Sera Prognostics Quote - SERA

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

8.43

Bid

5.49

Ask

8.50

Volume

123,377

7.80 Day's Range 8.56

1.52 52 Week Range 12.355

Market Cap

275.271M

Previous Close

8.03

Open

8.15

Last Trade

408

8.43

(priorref)

Last Trade Time

Financial Volume

US$ 1,020,674

VWAP

8.2728

Average Volume (3m)

155,120

Shares Outstanding

32,653,777

Dividend Yield

PE Ratio

-7.60

Earnings Per Share (EPS)

-1.11

Revenue

306k

Net Profit

-36.24M

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications. Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.

Sector

Medical Laboratories

Industry

Medical Laboratories

Website

www.seraprognostics.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Sera Prognostics Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker SERA. The last closing price for Sera Prognostics was US$8.03. Over the last year, Sera Prognostics shares have traded in a share price range of US$ 1.52 to US$ 12.355.

Sera Prognostics currently has 32,653,777 shares outstanding. The market capitalization of Sera Prognostics is US$262.21 million. Sera Prognostics has a price to earnings ratio (PE ratio) of -7.60.

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 PR Newswire SALT LAKE CITY, July 25, 2024 SALT LAKE CITY, July 25...

Form 4 - Statement of changes in beneficial ownership of securities

Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial

Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial PR Newswire SALT LAKE CITY, July 9, 2024...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.51	6.43939393939	7.92	8.56	7.25	117613	7.86239026	CS
4	2.48	41.6806722689	5.95	8.56	5.23	141657	6.73035876	CS
12	-2.39	-22.0887245841	10.82	11.05	4.98	155120	7.55659928	CS
26	2.23	35.9677419355	6.2	12.355	4.98	187714	8.44312771	CS
52	5.51	188.698630137	2.92	12.355	1.52	487120	5.95345543	CS
156	-1.39	-14.1547861507	9.82	13.51	1.1	308158	4.5386142	CS
260	-6.58	-43.8374417055	15.01	15.5	1.1	310543	4.65280441	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BSXBelo Sun Mining Corp	$ 0.055 (22.22%)	391.19k
KRNKarnalyte Resources Inc	$ 0.14 (21.74%)	18k
GMTNGold Mountain Mining Corp	$ 0.035 (16.67%)	1.5k
EEnterprise Group Inc	$ 1.34 (16.52%)	968.32k
YCMCommerce Split Corp	$ 2.25 (14.80%)	400
VRTSGamelancer Media Corp	$ 0.015 (-25.00%)	37k
SMCSulliden Mining Capital Inc	$ 0.015 (-25.00%)	3.8k
BNGBengal Energy Ltd	$ 0.02 (-20.00%)	11k
HBPHelix BioPharma Corp	$ 0.225 (-16.67%)	501
FLNTFlint Corporation	$ 0.025 (-16.67%)	70k
BTEBaytex Energy Corp	$ 4.76 (-5.93%)	13.23M
RYRoyal Bank of Canada	$ 153.06 (1.02%)	12.3M
ATHAthabasca Oil Corporation	$ 5.58 (4.30%)	4.92M
TDToronto Dominion Bank	$ 80.49 (0.56%)	4.36M
MFCManulife Financial Corporation	$ 35.96 (0.73%)	4.05M